Compare VLRS & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLRS | DSGN |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | Mexico | United States |
| Employees | 7098 | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 923.4M | 819.6M |
| IPO Year | N/A | 2021 |
| Metric | VLRS | DSGN |
|---|---|---|
| Price | $9.01 | $12.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $9.16 | ★ $15.25 |
| AVG Volume (30 Days) | 512.7K | ★ 881.5K |
| Earning Date | 04-27-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.96 | N/A |
| Revenue Next Year | $12.62 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.17 | $3.33 |
| 52 Week High | $10.80 | $17.25 |
| Indicator | VLRS | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 70.53 | 58.30 |
| Support Level | $8.59 | $11.94 |
| Resistance Level | $9.81 | $13.54 |
| Average True Range (ATR) | 0.39 | 0.63 |
| MACD | 0.16 | 0.24 |
| Stochastic Oscillator | 90.00 | 88.26 |
Controladora Vuela Compania de Aviacion SAB de CV is a low-cost airline flying to Mexico, the United States, Central, and South America. It uses promotional fares to stimulate demand, and the base fares are priced to compete with long-distance bus fares in Mexico. Revenues from the air transportation of passengers are recognized earlier when the service is provided or when the non-refundable ticket expires on the date of the scheduled travel. Non-passenger revenues include revenues generated from other non-passenger services and cargo services. The Company has two geographic areas identified as domestic (Mexico) and international (United States of America, Central America, and South America).
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.